Details of the Drug

General Information of Drug (ID: DMY3T0L)

Drug Name

DS-1211

Synonyms

N-Acetyl-D-leucine; 19764-30-8; Ac-D-Leu-OH; D-leucine, N-acetyl-; N-Acetyl-R-leucine; (2R)-2-acetamido-4-methylpentanoic acid; Acetylleucine, D-; Acetylleucine, (R)-; (R)-2-acetamido-4-methylpentanoic acid; Leucine, N-acetyl-, D-; acetyl-d-leucine; 91WU82GA22; MFCD00066069; 2,N-Acetyl-D-leucine; D-acetylleucine; UNII-91WU82GA22; (R)-acetylleucine; N-acetyl-D-Leu; NCGC00094935-01; N-acetyl-(D)-leucine; SCHEMBL714003; CHEMBL174357; CHEBI:94479; DTXSID50361310; CHEBI:146296; WXNXCEHXYPACJF-SSDOTTSWSA-N; HY-Y1080; s4514; AKOS016842336; AKOS025117328; CCG-266380; CS-W020713; DS-1211; FD21901; NCGC00094935-02; AC-22376; A0713; AM20090137; A-1455; A20910; EN300-321381; Q-100200; BRD-K05831461-001-01-8; Z851793110

Indication

Disease Entry	ICD 11	Status	REF
Pseudoxanthoma elasticum	EC40	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C8H15NO3
Canonical SMILES: CC(C)CC(C(=O)O)NC(=O)C
InChI: InChI=1S/C8H15NO3/c1-5(2)4-7(8(11)12)9-6(3)10/h5,7H,4H2,1-3H3,(H,9,10)(H,11,12)/t7-/m1/s1
InChIKey: WXNXCEHXYPACJF-SSDOTTSWSA-N

Cross-matching ID

PubChem CID: 1241420
TTD ID: D29GPF

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alkaline phosphatase tissue-nonspecific (ALPL)	TTMR5UV	PPBT_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Pseudoxanthoma elasticum

ICD Disease Classification

EC40

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Alkaline phosphatase tissue-nonspecific (ALPL)	DTT	ALPL	4.67E-13	-0.15	-0.79

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05569252) A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals With PseudoXanthoma Elasticum. U.S.National Institutes of Health.
2	In Vitro and In Vivo Pharmacological Profiles of DS-1211, a Novel Potent, Selective, and Orally Bioavailable Tissue-Nonspecific Alkaline Phosphatase Inhibitor. J Bone Miner Res. 2022 Oct;37(10):2033-2043.